{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:47:32Z","timestamp":1761101252380},"reference-count":30,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2014,9,25]],"date-time":"2014-09-25T00:00:00Z","timestamp":1411603200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J of Clinical Hypertension"],"published-print":{"date-parts":[[2014,12]]},"abstract":"This study assessed the risk of new\u2010onset gout following prescribing of hydrochlorothiazide (HCTZ<\/jats:styled-content>) compared with chlorthalidone (CTD<\/jats:styled-content>). This retrospective cohort analysis used administrative claims from 2000 to 2012 to identify patients aged 18 to 89\u00a0years with hypertension who were prescribed CTD<\/jats:styled-content> or HCTZ<\/jats:styled-content>. Patients were excluded if they had a prior diagnosis of gout, conditions or prescription claims for medications that alter risk of gout, or if they switched between these two diuretics. A total of 1011 patients prescribed CTD<\/jats:styled-content> were matched with 2022 patients prescribed HCTZ<\/jats:styled-content> based on age, sex, and Chronic Condition Indicator. New\u2010onset gout occurred in 17 of 1011 (1.68%) patients in the CTD<\/jats:styled-content> group and in 26 of 2022 (1.29%) patients in the HCTZ<\/jats:styled-content> group (P<\/jats:italic>=.27). The number of days to first occurrence of gout was 183.6\u00a0days and 152.7\u00a0days in the CTD<\/jats:styled-content> and HCTZ<\/jats:styled-content> groups, respectively (P<\/jats:italic>=.39). The mean daily dose was 22.7\u00a0mg for CTD<\/jats:styled-content> and 24.3\u00a0mg for HCTZ<\/jats:styled-content>, and the median dose of both CTD<\/jats:styled-content> and HCTZ<\/jats:styled-content> was 25\u00a0mg at the time of new\u2010onset gout. Patients prescribed CTD<\/jats:styled-content> for hypertension have a similar risk of developing new\u2010onset gout compared with patients prescribed similar doses of HCTZ<\/jats:styled-content>.<\/jats:p>","DOI":"10.1111\/jch.12413","type":"journal-article","created":{"date-parts":[[2014,9,25]],"date-time":"2014-09-25T12:10:19Z","timestamp":1411647019000},"page":"864-868","source":"Crossref","is-referenced-by-count":9,"title":["Comparison of New\u2010Onset Gout in Adults Prescribed Chlorthalidone vs Hydrochlorothiazide for Hypertension"],"prefix":"10.1111","volume":"16","author":[{"given":"Liza","family":"Wilson","sequence":"first","affiliation":[{"name":"Department of Family Medicine School of Medicine University of Missouri \u2010 Kansas City Kansas City MO"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kavita V.","family":"Nair","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy Skaggs School of Pharmacy and Pharmaceutical Sciences University of Colorado Anschutz Medical Campus Aurora CO"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph J.","family":"Saseen","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy Skaggs School of Pharmacy and Pharmaceutical Sciences University of Colorado Anschutz Medical Campus Aurora CO"},{"name":"Department of Family Medicine School of Medicine University of Colorado Anschutz Medical Campus Aurora CO"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,9,25]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21772"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21773"},{"key":"e_1_2_9_4_1","doi-asserted-by":"crossref","unstructured":"ZhuY PandyaBJ ChoiKH.Prevalence of gout in the US general population: the NHANES survey 2007\u20102008. In ISPOR 13th Annual European Congress. Prague Czech Republic 2010.","DOI":"10.1016\/S1098-3015(11)72163-5"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-7176.2012.00674.x"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes183"},{"key":"e_1_2_9_7_1","volume-title":"Pharmacotherapy: A Pathophysiologic Approach","author":"Ernst ME","year":"2011"},{"key":"e_1_2_9_8_1","unstructured":"IMS Institute for Healthcare Informatics.Declining medicine use and costs: for better or worse? A review of the use of medicines in the United States in 2012.http:\/\/tinyurl.com\/n8s8bs6. Accessed August 2013."},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(91)90439-5"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.82.5.1616"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1991.03460240051027"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-199715110-00019"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.23.2981"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.284427"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000203309.07140.d3"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0907219"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.108.189141"},{"key":"e_1_2_9_18_1","unstructured":"Chronic Condition Indicator for ICD\u20109\u2010CM.http:\/\/www.hcup-us.ahrq.gov\/toolssoftware\/chronic\/chronic.jsp. Accessed June 25 2014."},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22067"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0b013e31820543c5"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes253"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket265"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq363"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes211"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2011.11.008"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(97)00101-7"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1797.2006.00577.x"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.33315"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.38203"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.112.191106"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22067"}],"container-title":["The Journal of Clinical Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjch.12413","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjch.12413","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jch.12413","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T23:19:21Z","timestamp":1695511161000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jch.12413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,25]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["10.1111\/jch.12413"],"URL":"https:\/\/doi.org\/10.1111\/jch.12413","archive":["Portico"],"relation":{},"ISSN":["1524-6175","1751-7176"],"issn-type":[{"value":"1524-6175","type":"print"},{"value":"1751-7176","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,25]]}}}